BASKING RIDGE, N.J.
Aug. 7, 2012
/PRNewswire/ -- Mylan Specialty L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), and Pfizer Inc. (NYSE: PFE) today announced a license agreement, under which Pfizer will obtain the exclusive rights to market and sell EpiPen® Injection 0.3/0.15mg in
. These products, known in the U.S. as EpiPen® (epinephrine) 0.3mg and EpiPen Jr® (epinephrine) 0.15mg Auto-Injectors, are for self-administration for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise or unknown triggers. EpiPen Injection is the only approved epinephrine auto-injector in
"We are very excited to extend our partnership with Pfizer to this important market," said Mylan Chief Executive Officer
. "Last year, we announced that the Japanese Ministry of Health, Labour and Welfare approved National Health Insurance price listing for EpiPen Injection. We have built on this positive momentum by recently launching our next-generation EpiPen Injection in
. We look forward to achieving success with Pfizer as our partner that furthers our commitment to better serve the people of
who suffer from life-threatening allergies."
Under the terms of the agreement, the exclusive rights to market and sell the next-generation EpiPen Injection in
will be transferred to Pfizer from Mylan Seiyaku. The next-generation EpiPen Injection and EpiPen Auto-Injector are currently available in
, the U.S.,
and certain European countries.
"Pfizer and Mylan share a deep commitment to serve the people of
who are at risk for anaphylaxis," said
, President Pfizer Japan. "This agreement will help us to better address this important public health issue in
– from improving awareness and preparedness, to expanding access to treatment – through Pfizer's existing commercial infrastructure and market expertise."
The financial terms of the agreement were not disclosed.